Evaluating Clinical Safety of BTK Inhibitors: Cardiovascular Events and Drug-Drug Interactions

Bruton tyrosine kinase inhibitors (BTKis) are standard therapies for B-cell malignancies, including relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This study focuses on CLL/SLL. Although second-generation BTKis offer increased selectivity, their cardiovascular (CV) safety and potential drug-drug interactions (DDIs) remain incompletely characterized. This study describes CV toxicity and cytochrome P450 3A4 (CYP3A4)–mediated interactions of covalent (cBTKi) and noncovalent BTKi (ncBTKi) to inform safer therapy selection.